Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study

被引：0
|
作者：
Steven A. Yarows
Suzanne Oparil
Samir Patel
Hui Fang
Jack Zhang
机构：
[1] Chelsea Internal Medicine/IHA,
[2] UAB Vascular Biology and Hypertension Program,undefined
[3] Novartis Pharmaceuticals Corporation,undefined
[4] Chelsea Internal Medicine,undefined
来源：
Advances in Therapy | 2008年 / 25卷
关键词：
aliskiren; angiotensin receptor blocker; blood pressure; combination therapy; direct renin inhibitor; stage 2 hypertension; valsartan;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study
    Yarows, Steven A.
    Oparil, Suzanne
    Patel, Samir
    Fang, Hui
    Zhang, Jack
    ADVANCES IN THERAPY, 2008, 25 (12) : 1288 - 1302
  • [2] Antihypertensive efficacy of aliskiren/hydrochlorothiazide (HCT) combinations in patients with stage 2 hypertension: Subgroup analysis of a randomized, double-blind, factorial trial
    Calhoun, David A.
    Villamil, Alberto S.
    Chrysant, Steven G.
    Schober, Bonnie
    Fang, Hui
    Zhang, Jack
    HYPERTENSION, 2008, 52 (04) : E97 - E97
  • [3] Aliskiren in combination with valsartan lowers blood pressure more effectively than either agent alone in patients with stage 2 hypertension: Subgroup analysis of an 8-week double-blind study
    Yarows, Steven A.
    Oparil, Suzanne
    Patel, Samir
    Arora, Vipin
    Zhang, Jack
    HYPERTENSION, 2008, 52 (04) : E97 - E97
  • [4] Aliskiren Alone or in Combination With Hydrochlorothiazide in Patients With the Lower Ranges of Stage 2 Hypertension: The ACQUIRE Randomized Double-Blind Study
    Black, Henry R.
    Kribben, Andreas
    Palacios, Fernando Aguirre
    Bijarnia, Mahendra
    Laflamme, Annik K.
    Baschiera, Fabio
    NEW FRONTIERS IN HEART DISEASE, 2011, : 183 - 196
  • [5] Aliskiren Alone or in Combination With Hydrochlorothiazide in Patients With the Lower Ranges of Stage 2 Hypertension: The ACQUIRE Randomized Double-Blind Study
    Black, Henry R.
    Kribben, Andreas
    Aguirre Palacios, Fernando
    Bijarnia, Mahendra
    Laflamme, Annik K.
    Baschiera, Fabio
    JOURNAL OF CLINICAL HYPERTENSION, 2010, 12 (12): : 917 - 926
  • [6] Valsartan Improves Endothelial Dysfunction in Hypertension: A Randomized, Double-Blind Study
    Tzemos, Nikolaos
    Lim, Pitt O.
    MacDonald, Thomas M.
    CARDIOVASCULAR THERAPEUTICS, 2009, 27 (03) : 151 - 158
  • [7] Comparative Efficacy of Aliskiren Monotherapy and Ramipril Monotherapy in Patients with Stage 2 Systolic Hypertension: Subgroup Analysis of a Double-blind, Active Comparator Trial
    Andersen, Karl
    Weinberger, Myron H.
    Egan, Brent
    Constance, Christian M.
    Wright, Melanie
    Lukashevich, Valentina
    Keefe, Deborah L.
    CARDIOVASCULAR THERAPEUTICS, 2010, 28 (06) : 344 - 349
  • [8] Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial
    Oparil, Suzanne
    Yarows, Steven A.
    Patel, Samir
    Fang, Hui
    Zhang, Jack
    Satlin, Andrew
    LANCET, 2007, 370 (9583): : 221 - 229
  • [9] Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double-blind, multifactorial study
    Littlejohn, T. W., III
    Jones, S. W.
    Zhang, J.
    Hsu, H.
    Keefe, D. L.
    JOURNAL OF HUMAN HYPERTENSION, 2013, 27 (05) : 321 - 327
  • [10] Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double-blind, multifactorial study
    T W Littlejohn
    S W Jones
    J Zhang
    H Hsu
    D L Keefe
    Journal of Human Hypertension, 2013, 27 : 321 - 327
12345